MRD-negative duration following latest line of therapy predicts long-term PFS in real-world multiple myeloma patients.
Chen LY, Thibaud S, Bodnar S, Chari A, Richter J, Cho HJ, Sanchez LJ, Rodriguez C, Rossi AC, Richard S, Parekh S, Jagannath S.
Chen LY, et al. Among authors: cho hj.
Blood Adv. 2024 Nov 15:bloodadvances.2024014097. doi: 10.1182/bloodadvances.2024014097. Online ahead of print.
Blood Adv. 2024.
PMID: 39546749
No abstract available.